Cognetix Inc., a Salt Lake biotechnology company, recently announced that it has received $6 million to fund its research with marine organism compounds.

Researchers at the company believe that the compounds, known as conopeptides, can give therapeutic relief to people suffering from nervous system disorders.The conopeptides may be used to develop drugs to treat the effects of epilepsy, strokes, Parkinson's disease, schizophrenia and other disorders.

Cognetix's funding comes from Zesiger Capital Group LLC of New York City.